drugset / Trial / NCT03551210

Efficacy and Safety of Nemonoxacin vs Levofloxacin in Adult Patients With Community-Acquired Pneumonia

NCT03551210

Phase 3 Completed 342 enrolled R-Pharm OCT Clinical Trials · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study was to evaluate the clinical efficacy of treatment with Nemonoxacin compared with Tavanic® in patients with community-acquired pneumonia (CAP).

Timeline

Start
2016-05-04
Primary completion
2017-12-13
Completion
2017-12-26

Drugs

EvaluationDrugModalityDoseRoute
Comparator Levofloxacin Small molecule 500 mg Intravenous
Subject Nemonoxacin Small molecule 500 mg Intravenous

Indications